rosonabant rosonabant rosonabant (inn; e-6776) is a drug acting as a cb1 receptor antagonist/inverse agonist that was under investigation by esteve as an appetite suppressant for the treatment of obesity. development of the drug for clinical use was apparently halted shortly after the related cb1 antagonist rimonabant was discontinued in november 2008, due to the reports of severe psychiatric adverse effects such as anxiety, depression, and suicidal ideation associated with it and with similarly acting agents. rosonabantclinical dataatc codenoneidentifiers iupac name (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-n-(1-piperidinyl)-4,5-dihydro-1h-pyrazole-3-carboxamide cas number861151-12-4pubchem cid11316914chemspider9491881unii7x5ry2t485comptox dashboard (epa)dtxsid201006613 chemical and physical dataformulac21h21cl3n4omolar mass451.78 g·mol−13d model (jsmol)interactive image smiles o=c(nn1ccccc1)\c4=n\n(c2ccc(cl)cc2cl)c(c3ccc(cl)cc3)c4 inchi inchi=1s/c21h21cl3n4o/c22-15-6-4-14(5-7-15)20-13-18(21(29)26-27-10-2-1-3-11-27)25-28(20)19-9-8-16(23)12-17(19)24/h4-9,12,20h,1-3,10-11,13h2,(h,26,29)key:wmmmjgkfkkbrqr-uhfffaoysa-n